Saturday, September 12

7:30 AM – 1:00 PM CST

In-Person Conference
Andrews Academic Tower
Conference Rooms A, B, and C
800 Stanton L. Young Blvd Oklahoma City, OK 73104

OSCO Trainee Abstract Competition

The Oklahoma Society of Clinical Oncology (OSCO) invites all trainees to submit Trainee Research Abstract competition during our annual Best of ASCO Fall Conference conducted on September 12th, 2026. Abstract submissions are due August 24, 2026.

There is no fee for trainees, but registration will be required in advance.

Submission Period is Now Closed!

OSCO Presents Best of ASCO®

The Oklahoma Society of Clinical Oncology, Inc. OSCO invites you to attend our 2026 In-Person Fall Conference, an officially licensed Best of ASCO® event.   This conference will highlight the foremost research and strategies in oncology that were presented by speakers at the 2026 American Society of Clinical Oncology’s (ASCO®) Annual Meeting.  This conference is designed to update the educational needs of Hematologists/Oncologists, Nurses, Pharmacists, Physician Assistants, and other healthcare professionals specializing in oncology.

There is no fee for this conference, but registration is required.

• BEST OF ASCO®is an officially licensed program of the American Society of Clinical Oncology, Inc. (ASCO®).
• This conference is provided by the Oklahoma Society of Clinical Oncology, Inc.

For more general information, contact OSCO Executive Director Kathleen Musson by e-mail to kmusson@nextwavegroup.net

Registration for this Event has Closed!

For Corporate Member/Sponsor Registration ONLY:

• Exhibit at this Meeting: Corporate Members who want to Exhibit at this meeting, please contact Pam Moran at pmoran@nextwavegroup.net to register for your space at this meeting.
• Not a Corporate Member Yet?
  View our Corporate Membership packages.

FOR OSCO Members/Other Allied Professionals Registration ONLY Click Below:

8:00 – 8:15 AM

8:15 – 9:15 AM

Welcome & Opening Remarks

Session I – Precision Treatment Strategies in Lung Cancer
Guest Speaker: Laercio DaSilva, MD 

• ​ Updates in early stage lung cancer with ICPI and  Targeted Therapy
•  Integrating DLL3-Targeted Therapy in Small Cell Lung Cancer Treatment Paradigms

Laercio DaSilva, MD, is a thoracic medical oncologist and assistant professor at Emory University’s Winship Cancer Institute. His work primarily focuses on the clinical and translational development of novel immunotherapies for thoracic tumors. Dr. DaSilva completed his medical oncology training at the National Cancer Institute, where he served as Chief Fellow. He holds a medical degree from the Faculdade de Ciências Médicas da Santa Casa de São Paulo and completed his internal medicine residency at MetroWest Medical Center/Tufts University School of Medicine.

9:15 – 10:15 AM

Session II – Precision Medicine and Biomarker-Driven Care in Gastrointestinal Oncology
Guest Speaker: Karen Riggins, MD, PhD

• HER2 Directed Therapy in Upper GI Cancers: Integrating HER2 positive treatment in gastro-esophageal adenocarcinoma
• The KRAS Revolution in Pancreatic Cancer: Integrating KRAS-Directed therapy in Pancreatic cancer

Karen Riggins, MD, PhD is a gastrointestinal (GI) oncologist and physician-scientist whose research program is dedicated to elucidating the molecular mechanisms underlying early-onset GI cancers, with a particular focus on health equity in underrepresented populations. Her translational research integrates epigenomic and microbiome analyses to investigate the pathogenesis of early-onset colorectal cancer (EOCRC, defined as CRC diagnosed before age 50), a disease whose rising incidence disproportionately affects racial and ethnic minorities. Under the mentorship of Dr. Lanlan Shen, Dr. Riggins has leveraged a unique cohort of predominantly minority EOCRC patients within the Baylor College of Medicine (BCM)/Harris Health System to conduct the first comprehensive characterization of the EOCRC methylome at single-base resolution using whole-genome bisulfite sequencing (WGBS). Their analyses revealed distinct epigenetic features of EOCRC—including global hypomethylation, promoter-specific hypermethylation, and dysregulation of the TGF-β signaling pathway—that were not previously captured in The Cancer Genome Atlas (TCGA). These findings nominate novel biomarkers and mechanistic targets for EOCRC in populations historically underrepresented in genomic studies. In parallel with her translational program, Dr. Riggins serves as Principal Investigator for several clinical trials in the management of advanced colorectal and gastroesophageal cancers, ensuring that her research questions remain grounded in the clinical needs of the patients she serves.

10:15 – 11:00 AM

11:00 – 12:00 PM

Networking Break, Poster Walk & Exhibits

Session III – Practice-Changing Advances in Genitourinary Oncology
Guest Speaker: Dr. Arnab Basu, MBBS

• Adjuvant Therapy for Renal Cell Carcinoma in 2026
• Perioperative Management of Muscle-Invasive Bladder Cancer in 2026

Dr. Basu, M.B.B.S., M.P.H., F.A.C.P., is a medical oncologist specializing in the care of genitourinary cancers, with a special interest in renal cell carcinoma and urothelial carcinoma. He also has an interest in biomarkers for improving treatment decision making. Dr. Basu has previously served as the Section Chief for Genitourinary Oncology and the chair of the Genitourinary working group at the University of Alabama Oneal Comprehensive Cancer Center in Birmingham. He is a recipient of the Young Investigator Award from the National Comprehensive Cancer Network.

12:00 – 12:45 PM

Industry Lunch Symposium (Natera): 

•  Integrating ctDNA into Routine Oncology Practice 

12:45 – 1:00 PM

Awards Ceremony & Closing Remarks